Browse Studies — Arctuva

Phase 1

An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therap…

Advanced HR+/HER2- Breast Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07604571

Phase 1

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimizat…

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06726148

Phase 1

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimizatio…

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07288359